These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 22682429

  • 1. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.
    Westover AN, Halm EA.
    BMC Cardiovasc Disord; 2012 Jun 09; 12():41. PubMed ID: 22682429
    [Abstract] [Full Text] [Related]

  • 2. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.
    Arch Pediatr; 2014 Jan 09; 21(1):108-12. PubMed ID: 24309201
    [Abstract] [Full Text] [Related]

  • 3. Recommendation for Long-term Management of Adult Attention-Deficit/Hyperactivity Disorder in Military Populations, Veterans, and Dependents: A Narrative Review.
    Baughman DJ, Watson CM, Beich JW, Herboso MNJ, Cuttie LK, Marlyne AC.
    Mil Med; 2024 May 18; 189(5-6):e1343-e1352. PubMed ID: 37878798
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong IC, Zuddas A, Rosenthal E, Buitelaar JK, ADDUCE consortium.
    CNS Drugs; 2017 Mar 18; 31(3):199-215. PubMed ID: 28236285
    [Abstract] [Full Text] [Related]

  • 5. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J, Knecht C, Szerman N, Martinez MI.
    CNS Drugs; 2013 Jan 18; 27(1):15-30. PubMed ID: 23160939
    [Abstract] [Full Text] [Related]

  • 6. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
    Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, Marcus SC.
    J Am Acad Child Adolesc Psychiatry; 2012 Feb 18; 51(2):147-56. PubMed ID: 22265361
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.
    Eaton C, Yong K, Walter V, Mbizvo GK, Rhodes S, Chin RF.
    Cochrane Database Syst Rev; 2022 Jul 13; 7(7):CD013136. PubMed ID: 35844168
    [Abstract] [Full Text] [Related]

  • 9. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN, Wilde AA.
    Ned Tijdschr Geneeskd; 2006 Aug 05; 150(31):1713-4. PubMed ID: 16924941
    [Abstract] [Full Text] [Related]

  • 10. [Attitude to questionable cadiac risks in stimulant administration].
    Fegert JM, Hebebrand J, Kommission Entwicklungspsychopharmakologie der drei Fachgesellschaften.
    Z Kinder Jugendpsychiatr Psychother; 2006 Jul 05; 34(4):295-7. PubMed ID: 16927572
    [No Abstract] [Full Text] [Related]

  • 11. Stimulants and sudden death: what is a physician to do?
    Wilens TE, Prince JB, Spencer TJ, Biederman J.
    Pediatrics; 2006 Sep 05; 118(3):1215-9. PubMed ID: 16951018
    [Abstract] [Full Text] [Related]

  • 12. Risk of stroke in prescription and other amphetamine-type stimulants use: A systematic review.
    Indave BI, Sordo L, Bravo MJ, Sarasa-Renedo A, Fernández-Balbuena S, De la Fuente L, Sonego M, Barrio G.
    Drug Alcohol Rev; 2018 Jan 05; 37(1):56-69. PubMed ID: 28485090
    [Abstract] [Full Text] [Related]

  • 13. Stimulants and Pediatric Cardiovascular Risk.
    Zito JM, Burcu M.
    J Child Adolesc Psychopharmacol; 2017 Aug 05; 27(6):538-545. PubMed ID: 27258470
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.
    Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson M.
    BMJ; 2012 Jul 18; 345():e4627. PubMed ID: 22809800
    [Abstract] [Full Text] [Related]

  • 15. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS, Bell EA, Erramouspe J.
    Ann Pharmacother; 2014 Oct 18; 48(10):1350-5. PubMed ID: 24982313
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
    Awudu GA, Besag FM.
    Drug Saf; 2014 Sep 18; 37(9):661-76. PubMed ID: 25124483
    [Abstract] [Full Text] [Related]

  • 17. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.
    Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV.
    JAMA; 2011 Dec 28; 306(24):2673-83. PubMed ID: 22161946
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.
    Dalsgaard S, Kvist AP, Leckman JF, Nielsen HS, Simonsen M.
    J Child Adolesc Psychopharmacol; 2014 Aug 28; 24(6):302-10. PubMed ID: 24956171
    [Abstract] [Full Text] [Related]

  • 19. Acute myocardial infarction induced by concurrent use of adderall and alcohol in an adolescent.
    Sharma J, de Castro C, Chatterjee P, Pinto R.
    Pediatr Emerg Care; 2013 Jan 28; 29(1):84-8. PubMed ID: 23283274
    [Abstract] [Full Text] [Related]

  • 20. Use of prescription stimulant for Attention Deficit Hyperactivity Disorder in Aboriginal children and adolescents: a linked data cohort study.
    Ghosh M, Holman CD, Preen DB.
    BMC Pharmacol Toxicol; 2015 Dec 09; 16():35. PubMed ID: 26646429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.